Cancer Immunology – News and Features

UF Health researchers found that a toxin in Campylobacter jejuni accelerates colorectal cancer metastasis, linking gut bacteria to cancer spread. The study revealed how the toxin activates metastasis-associated signaling pathways.

University of Alabama researchers reveal a key mechanism in BK polyomavirus replication, challenging existing models. The virus relies on host cell DNA replication, with its TAg protein expressed only after the first replication round.

UCSF researchers have engineered T cells to temper overactive immune responses by targeting inflammation and soothing immune activity. The technology successfully protected transplanted pancreatic islet cells in a type 1 diabetes model.

Researchers have built a synthetic receptor with broad potential to program cell activity, including immune response and neurological signaling.

University of Michigan researchers identified UBA1 as a key player in immunotherapy resistance. Inhibiting UBA1 boosts T-cell recruitment, converting cold tumors to hot, and enhancing the effectiveness of immune checkpoint blockade therapies.

Researchers have designed a novel immunotherapy, based on a tri-specific antibody, for glioblastoma, the deadliest form of brain cancer.

Focused ultrasound can allow CRISPR gene editing to be precisely targeted and controlled remotely.

A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in a Phase Ib/II trial.

A study from Spain’s CNIO identifies genetic alterations linked to STAG2 loss, driving aggressiveness in Ewing sarcoma. These changes increase metastasis and impact immune response, offering new prognostic markers and therapeutic targets.

Researchers revealed that checkpoint inhibitors, a powerful cancer immunotherapy, impair B cell function, reducing antibody diversity and increasing infection risk. They suggest immunoglobulin replacement therapy as a preventive measure.